Publications

Selected Publications

View our full list of publications on PubMed

Matthew-Onabanjo, A.N., Nortey, G., Matulewicz, R.S., Basak, R., Culton, D.A., Weaver, K.N., Gallagher, K.K., Tan, H.-J., Rose, T.L., Milowsky, M., Bjurlin, M.A., 2023. Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot. Curr. Probl. Cancer 47, 100958.

Clark-Garvey, S., Damrauer, J.S., Milowsky, M.I., 2023. Cancer Associated Fibroblasts: An Understudied but Critical Component of the Tumor Microenvironment in Urothelial Cancer. Eur. Urol. Oncol. 6, 376–377.

Flaig, T.W., Tangen, C.M., Daneshmand, S., Alva, A.S., Lucia, M.S., McConkey, D.J., Theodorescu, D., Goldkorn, A., Milowsky, M.I., Bangs, R., MacVicar, G.R., Bastos, B.R., Fowles, J.S., Gustafson, D.L., Plets, M., Thompson, I.M., Lerner, S.P., 2023. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur. Urol. 84, 341–347.

Koshkin, V.S., Henderson, N., James, M., Natesan, D., Freeman, D., Nizam, A., Su, C.T., Khaki, A.R., Osterman, C.K., Glover, M.J., Chiang, R., Makrakis, D., Talukder, R., Lemke, E., Olsen, T.A., Jain, J., Jang, A., Ali, A., Jindal, T., Chou, J., Friedlander, T.W., Hoimes, C., Basu, A., Zakharia, Y., Barata, P.C., Bilen, M.A., Emamekhoo, H., Davis, N.B., Shah, S.A., Milowsky, M.I., Gupta, S., Campbell, M.T., Grivas, P., Sonpavde, G.P., Kilari, D., Alva, A.S., 2022. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer 128, 1194–1205.

Basch, E., Schrag, D., Henson, S., Jansen, J., Ginos, B., Stover, A.M., Carr, P., Spears, P.A., Jonsson, M., Deal, A.M., Bennett, A.V., Thanarajasingam, G., Rogak, L.J., Reeve, B.B., Snyder, C., Bruner, D., Cella, D., Kottschade, L.A., Perlmutter, J., Geoghegan, C., Samuel-Ryals, C.A., Given, B., Mazza, G.L., Miller, R., Strasser, J.F., Zylla, D.M., Weiss, A., Blinder, V.S., Dueck, A.C., 2022. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer. JAMA 327, 2413–2422.

Freudenburg, E., Bagheri, I., Srinivas, S., Martinez, A., Putluri, N., Klaassen, Z., Kamat, A.M., Konety, B.R., Kim, W.Y., Dyrskjøt, L., McConkey, D.J., Freedland, S.J., Black, P.C., Daneshmand, S., Catto, J.W.F., Williams, S.B., 2022. Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review. Cancer Causes Control 33, 1071–1081.

Saunders, K.E., Craig, J.C., Hoerres, D.L., Maygarden, S.J., Wobker, S.E., 2022. Less Is More. Am. J. Clin. Pathol. 158, 383–388.

Stover, A.M., Basak, R., Mueller, D., Lipman, R., Teal, R., Hilton, A., Giannone, K., Waheed, M., Smith, A.B., 2022. Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer. J. Urol. 208, 580–588.

Kukreja JB, Schroeck FR, Lotan Y, Gore JL, Ullman R, Lipman RR, et al Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy Urologic Oncol Seminars Orig Investigations 2022;40:9e19-9e27

Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma New Engl J Med 2021;384:2102–14

Truong AS, Zhou M, Krishnan B, Utsumi T, Manocha U, Stewart KG, et al Entinostat induces antitumor immune responses through immune editing of tumor neoantigens J Clin Invest 2021;131:e138560

Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, et al Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience Brit J Cancer 2021;125:1251–60

Rose TL, Harrison MR, Deal AM, Ramalingam S, Whang YE, Brower B, et al Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer J Clin Oncol 2021;39:3140–8

Carrot-Zhang J, Chambwe N, Damrauer JS, Knijnenburg TA, Robertson AG, Yau C, et al Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer Cancer Cell 2020;37:639-654e6

Kardos J, Rose TL, Manocha U, Wobker SE, Damrauer JS, Bivalaqua TJ, et al Development and validation of a NanoString BASE47 bladder cancer gene classifier Plos One 2020;15:e0243935

Nikas CV, Smith AB Goldilocks and the BCG: Bacillus Calmette-Guérin Dose Reduction in the Age of Shortage Eur Urol 2020;78:699–700 https://doiorg/101016/jeururo202005021

Manocha U, Kardos J, Selitsky S, Zhou M, Johnson SM, Breslauer C, et al RNA Expression Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder Reveals a Basal-Like Molecular Subtype Am J Pathology 2020;190:134–44

Saito R, Smith CC, Utsumi T, Bixby LM, Kardos J, Wobker SE, et al Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy Cancer Res 2018;78:canres01732018

Smith AB, Chisolm S, Deal A, Spangler A, Quale DZ, Bangs R, et al Patient-centered prioritization of bladder cancer research Cancer 2018;124:3136–44

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer Cell 2017;171:540-556e25

Kardos J, Chai S, Mose LE, Selitsky SR, Krishnan B, Saito R, et al Claudin-low bladder tumors are immune infiltrated and actively immune suppressed Jci Insight 2016;1:e85902

Rose TL, Deal AM, Nielsen ME, Smith AB, Milowsky MI Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer Cancer 2016;122:2012–20

Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology Proc National Acad Sci 2014;111:3110–5